|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Venetoclax is an oral BCL-2 protein inhibitor recently approved by the United States Food and Drug Administration (FDA) for use in combination with a hypomethylating agent (HMA) (azacitidine or decitabine) or low-dose cytarabine for front-line treatment of AML in older patients or those unfit for induction chemotherapy.
|
31628431 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Venetoclax (ABT-199), a BH3-mimetic and selective BCL-2 inhibitor, was recently approved by the US Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) in adult patients aged 75 years or older, or otherwise unable to tolerate intensive induction chemotherapy, in combination with either hypomethylating agents or low-dose cytarabine.
|
31118772 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
It was found that the antigens of Bcl-2 in acute myelogenous leukemia (AML) and acute lymphocytic (ALL) was higher than that in the normal (P < 0.01).
|
11245018 |
1998 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using inducible vectors and venetoclax to differentially target anti-apoptotic BCL-2 family members, BCL-2 and MCL1 emerged as critical and complementary proteins regulating cell survival in acute myeloid leukemia.
|
28751770 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, with the approval of the FMS-like tyrosine kinase 3 (FLT3) inhibitor Midostaurin a first targeted therapy has been introduced into the first-line therapy of younger patients with FLT3-mutated AML and several other small molecules targeting molecular alterations such as isocitrate dehydrogenase (IDH) mutations or the anti-apoptotic b-cell lymphoma 2 (BCL-2) protein are currently under investigation.
|
30626126 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Bcl-2/Bcl-xL/Bax and the Ras/Raf/MEK/ERK (MAPK) pathways are often deregulated in many human cancers and especially in acute lymphoblastic leukemia and acute myeloid leukemia.
|
24083449 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we have investigated the effect of exogenous and autocrine granulocyte-macrophage colony-stimulating factor (GM-CSF) on both bcl-2 expression and apoptosis in acute myeloid leukaemia (AML) cells.
|
8182935 |
1994 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of Bcl-2 via venetoclax synergistically enhances the efficacy of midostaurin and gilteritinib in FLT3-mutated AML.<i>See related commentary by Perl, p. 6567</i>.
|
31320594 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combined, venetoclax and alvocidib modulate the balance of BCL-2 family proteins through complementary, yet variable mechanisms favoring apoptosis, highlighting this combination as a promising therapy for AML or high-risk MDS with the capacity to overcome intrinsic apoptosis mechanisms of resistance.
|
29291023 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
We performed global specific gene expression profiling and functional pathway analysis in purified Sca1+ cells of two MDS transgenic mouse models that mimic human high-risk MDS (HR-MDS) and acute myeloid leukemia (AML) post MDS, with NRASD12 and BCL2 transgenes under the control of different promoters MRP8NRASD12/tethBCL-2 or MRP8[NRASD12/hBCL-2], respectively.
|
26817437 |
2016 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
The leukemic cell lines HL-60, KG1, GM-1, and K562 were bcl-2 positive together with 11 of 14 acute myeloid leukemias (AML) and three of three chronic myeloid leukemias (CML) in blast crises; six of seven CML were negative.
|
1536952 |
1992 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Leukemic cells of AML patients who achieved a complete remission (CR) after induction chemotherapy expressed less Bcl-2 than non-responder (NR) (69 CR, 23 NR; P = 0.05).
|
10602414 |
1999 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.
|
30623427 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Venetoclax is a specific B cell lymphoma 2 (BCL-2) inhibitor with promising activity against acute myeloid leukemia (AML), but its clinical efficacy as a single agent or in combination with hypomethylating agents (HMAs), such as azacitidine, is hampered by intrinsic and acquired resistance.
|
31666400 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
|
12423683 |
2002 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The current study determined whether a BCL2 gene single nucleotide polymorphism (SNP) could affect treatment outcomes in 99 AML patients excluding acute promyelocytic leukemia.
|
19520430 |
2010 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical results deriving from studies using B-cell lymphoma 2 (BCL-2) inhibitors in combination with standard AML agents, such as azacytidine, decitabine, low-dose cytarabine, provided promising results and strongly support the use of these agents in the treatment of AML patients, particularly of elderly patients.
|
30813354 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Curcumin down-regulates Bcl-2 and induces apoptosis in DNR-insensitive CD34+ AML cell lines and primary CD34+ AML cells.
|
21595920 |
2011 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Using a modified quantitative reverse transcriptase (RT) PCR assay in 57 patients with acute myeloid leukaemia (AML) from a Swiss Phase III multicentre study (SAKK 30/85), we measured the m-RNA expression of the genes from the multidrug resistance gene 1 (MDR1), the multidrug resistance associated protein (MRP), glutathione-S-transferase (GST) pi, bcl-2 and topoisomerase (topo) IIalpha.
|
9338618 |
1997 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
ABT-199, a potent and selective small-molecule antagonist of BCL-2, is being clinically vetted as pharmacotherapy for the treatment of acute myeloid leukemia (AML).
|
27283158 |
2016 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Herein, we focus on the role of single-agent BCL-2 inhibition in AML and review the clinical studies of venetoclax-based combination regimens and the evolving mechanisms of resistance.
|
31203996 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mechanistically, the increased sensitivity of AML cells to genotoxic agents is associated with alteration of BCL2 family proteins, particularly transcriptional upregulation of PMAIP1/NOXA.
|
27797294 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
BCL-2 inhibition with venetoclax is well tolerated and active in older patients with newly diagnosed AML and in the relapsed setting has activity that may be improved in combination with other therapies.
|
29982865 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.
|
28710745 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we report that removal of Mcl-1, but not loss or pharmacological blockade of Bcl-x(L), Bcl-2, or Bcl-w, caused the death of transformed AML and could cure disease in AML-afflicted mice.
|
22279045 |
2012 |